Search
Vanda Pharmaceuticals Inc
VNDAAdd to Watchlist
6.210USD
+0.160+2.64%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
373.44MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.64%
5 Days
+3.33%
1 Month
-0.64%
6 Months
-24.73%
Year to Date
-29.59%
1 Year
+24.95%
Key Figures
6.060Open
6.230High
859.11KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.43%Turnover Ratio
6.050Prev. Close
6.010Low
4.13MTurnover
LossP/E Static
1.33P/B
0.00%Div Yield TTM
-44.97%ROA
9.94052wk High
1.55Volume Ratio
-18.90MNet Profit
60.14MShares
-4.0541EPS TTM
0.63Beta
-60.48%ROE
4.14052wk Low
3.64%Amplitude
90.05%Gross Margin
373.44MMarket Cap
-0.91Reward/Risk
3.52%Risk Rate
TradingKey Stock Score of Vanda Pharmaceuticals Inc
Currency: USD Updated: 2026-07-02Key Insights
Vanda Pharmaceuticals Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 79 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.12.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Vanda Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Vanda Pharmaceuticals Inc Highlights
StrengthsRisks
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Overvalued
The company’s latest PE is -1.53, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 47.15M shares, decreasing 10.02% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 109.38K shares of this stock.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
14.125
Target Price
+133.47%
Upside Space
Vanda Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Vanda Pharmaceuticals Inc Info
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Ticker SymbolVNDA
CompanyVanda Pharmaceuticals Inc
CEOPolymeropoulos (Mihael Hristos)
Websitehttps://www.vandapharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Vanda Pharmaceuticals Inc (VNDA)?
The current price of Vanda Pharmaceuticals Inc (VNDA) is 6.21.
What is the symbol of Vanda Pharmaceuticals Inc?
The ticker symbol of Vanda Pharmaceuticals Inc is VNDA.
What is the 52-week high of Vanda Pharmaceuticals Inc?
The 52-week high of Vanda Pharmaceuticals Inc is 9.94.
What is the 52-week low of Vanda Pharmaceuticals Inc?
The 52-week low of Vanda Pharmaceuticals Inc is 4.14.
What is the market capitalization of Vanda Pharmaceuticals Inc?
The market capitalization of Vanda Pharmaceuticals Inc is 367.02M.
Is Vanda Pharmaceuticals Inc (VNDA) currently rated as Buy, Hold, or Sell?
According to analysts, Vanda Pharmaceuticals Inc (VNDA) has an overall rating of Buy, with a price target of 14.12.
What is the Earnings Per Share (EPS TTM) of Vanda Pharmaceuticals Inc (VNDA)?
The Earnings Per Share (EPS TTM) of Vanda Pharmaceuticals Inc (VNDA) is -3.74.